The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...

The medication is best known by Novo Nordisk's brand names Ozempic (approved for type 2 diabetes) and Wegovy (approved for obesity), which are both glucagon-like peptide-1 inhibitors (GLP-1s). RELATED ...

These foods slow digestion, reduce hunger, and stabilize insulin, offering weight management benefits. While they don’t ...

KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a lower risk for venous thromboembolism (VTE).

As GLP-1 drugs like Ozempic soar in popularity for weight loss, this film follows three people on their own GLP-1 journeys and explores how decades of diet culture and society’s relentless pursuit of ...

Ozempic, a weight loss drug that has exploded in use across America, has joined a list of treatments that started with benign intentions and evolved into a reflection of the modern weight loss and ...

Cardiometabolic disease biotech NeuroBo Pharmaceuticals is shaking up its corporate image with a complete rebrand. | ...

Inno Supps’ Trim Biome™ GLP-1 is designed to support the body’s natural production of GLP-1 through a unique blend of ...

Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GIP/GLP-1) ...

Glucagon-like peptide-1 receptor (GLP-1) agonists, particularly semaglutide, could be effective in reducing alcohol-related ...

The Ipsos survey of 1,078 adults found 24 of people would use weight-loss jabs if they were provided for free by the health service.